Search research articles
Contact Us
Filters
Showing results (101-110 of 116) with videos related to
Page
of 12
Sort By:
JAMA Network Open
|
June 25, 2024
Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial
Edward V Nunes, Sandra D Comer, Michelle R Lofwall, et al.
Journal of Hazardous Materials
|
October 14, 2023
Immobilizing arsenic in contaminated anoxic aquifer sediment using sulfidated and uncoated zero-valent iron (ZVI)
Thiago Augusto Formentini, Geert Cornelis, Jon Petter Gustafsson, et al.
Cancer Chemotherapy and Pharmacology
|
December 12, 2018
Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study
Marianne Pavel, Françoise Borson-Chazot, Anne Cailleux, et al.
Hospital Pharmacy
|
September 26, 2015
The State of Antimicrobial Stewardship in Michigan: Results of a Statewide Survey on Antimicrobial Stewardship Efforts in Acute Care Hospitals
Curtis D Collins, Dianne E Miller, Rachel M Kenney, et al.
Trials
|
May 2, 2024
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET
Simron Singh, Diego Ferone, Jaume Capdevila, et al.
Trials
|
January 16, 2024
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET
Simron Singh, Diego Ferone, Jaume Capdevila, et al.
JAMA Network Open
|
May 10, 2021
Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial
Nicholas Lintzeris, Adrian J Dunlop, Paul S Haber, et al.
Journal of Addiction Medicine
|
April 7, 2025
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial
Michelle R Lofwall, Edward V Nunes, Sharon L Walsh, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 8, 2024
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1
Diego Ferone, Pamela Freda, Laurence Katznelson, et al.
Addiction (Abingdon, England)
|
April 24, 2019
Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder
Michael Frost, Genie L Bailey, Nicholas Lintzeris, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 116) with videos related to
Sort By:
Page
of 12
JAMA Network Open
|
June 25, 2024
Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial
Edward V Nunes, Sandra D Comer, Michelle R Lofwall, et al.
Journal of Hazardous Materials
|
October 14, 2023
Immobilizing arsenic in contaminated anoxic aquifer sediment using sulfidated and uncoated zero-valent iron (ZVI)
Thiago Augusto Formentini, Geert Cornelis, Jon Petter Gustafsson, et al.
Cancer Chemotherapy and Pharmacology
|
December 12, 2018
Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study
Marianne Pavel, Françoise Borson-Chazot, Anne Cailleux, et al.
Hospital Pharmacy
|
September 26, 2015
The State of Antimicrobial Stewardship in Michigan: Results of a Statewide Survey on Antimicrobial Stewardship Efforts in Acute Care Hospitals
Curtis D Collins, Dianne E Miller, Rachel M Kenney, et al.
Trials
|
May 2, 2024
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET
Simron Singh, Diego Ferone, Jaume Capdevila, et al.
Trials
|
January 16, 2024
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET
Simron Singh, Diego Ferone, Jaume Capdevila, et al.
JAMA Network Open
|
May 10, 2021
Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial
Nicholas Lintzeris, Adrian J Dunlop, Paul S Haber, et al.
Journal of Addiction Medicine
|
April 7, 2025
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial
Michelle R Lofwall, Edward V Nunes, Sharon L Walsh, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 8, 2024
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1
Diego Ferone, Pamela Freda, Laurence Katznelson, et al.
Addiction (Abingdon, England)
|
April 24, 2019
Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder
Michael Frost, Genie L Bailey, Nicholas Lintzeris, et al.
Page
of 12